{"id":499491,"date":"2020-07-29T14:04:01","date_gmt":"2020-07-29T14:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=499491"},"modified":"2020-07-29T14:04:01","modified_gmt":"2020-07-29T14:04:01","slug":"dravet-syndrome-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dravet-syndrome-market-size-share-trends-epidemiology-forecast-till-2030_499491.html","title":{"rendered":"Dravet Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dravet Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Dravet Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Dravet Syndrome Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Dravet Syndrome (DS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total incident population of Dravet Syndrome in 7MM in 2017 was 30,820&nbsp;<\/li>\n<li>The number of Dravet Syndrome patients in the United States in 2017 was 20,912<\/li>\n<li>The number of Dravet Syndrome patients in Japan in 2017 was 2,766<\/li>\n<li>The age-specific incidence in the US was highest among 4&ndash;8 years old, followed by 9&ndash;13 years old patients in 2017<\/li>\n<li>The seizure-associated cases of Dravet Syndrome in Japan in 2017 was 1,369<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\" target=\"_blank\"><strong>Dravet Syndrome&nbsp;Market Insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/b340c2df027dd179af82fd4f7ac7a44a.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dravet Syndrome Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increase in research activities<\/li>\n<li>Increasing disease awareness<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dravet Syndrome Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Disease Burden<\/li>\n<li>Diagnostic Challenges<\/li>\n<li>Comparatively Reduced Focus<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dravet-syndrome-market\" target=\"_blank\">Request for sample pages<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dravet-syndrome-market\" target=\"_blank\">Table of contents<\/a><\/p>\n<p style=\"text-align: justify;\"><span>1 Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2 Executive Summary of Dravet Syndrome<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3 SWOT Analysis for Dravet Syndrome<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4 Dravet Syndrome Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1 Market Share (%) Distribution of Dravet Syndrome in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2 Market Share (%) Distribution of Dravet Syndrome in 2030<\/p>\n<p style=\"text-align: justify;\"><span>5 Dravet Syndrome: Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1 Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2 Clinical Features of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.2.1 Epilepsy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.2.2 Cognition<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.2.3 Movement disorders<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.2.4 Sudden Death<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3 Genetics of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.3.1 Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.3.2 Functional aspects of voltage gate sodium channel mutations<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.3.3 Detection of SCN1A mutations<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.3.4 Inheritance mode and pattern<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.3.5 Dravet Syndrome without SCN1A Alterations<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4 Signs and Symptoms of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5 Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.6 Diagnosis of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">5.6.1 Differential diagnosis<\/p>\n<p style=\"text-align: justify;\"><span>6 Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.1 Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6.2 Total Incidence of Dravet Syndrome in 7MM<\/p>\n<p style=\"text-align: justify;\"><span>7 Country Wise-Epidemiology of Dravet Syndrome<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8 United States<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1 Assumptions and Rationale<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2 Incident Population of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.3 Mutations associated with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.1 Incidence of Dravet Syndrome by Mutation Class<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3.2 Incidence of Dravet Syndrome by Mutation Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.4 Seizure associated cases of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.5 Gender-specific Incidence of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.6 Age-specific Incidence of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\"><span>9 EU-5<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">9.1 Assumptions and Rationale<\/p>\n<p style=\"text-align: justify;\"><span>10 Germany<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.1 Incident Population of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.2 Mutations associated with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">10.2.1 Incidence of Dravet Syndrome by Mutation Class<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">10.2.2 Incidence of Dravet Syndrome by Mutation Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.3 Seizure associated cases of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.4 Gender-specific Incidence of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10.5 Age-specific Incidence of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\"><span>11 France<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1 Incident Population of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2 Mutations associated with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.1 Incidence of Dravet Syndrome by Mutation Class<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.2 Incidence of Dravet Syndrome by Mutation Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.3 Seizure associated cases of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.4 Gender-specific Incidence of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.5 Age-specific Incidence of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\"><span>12 Italy<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1 Incident Population of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2 Mutations associated with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.1 Incidence of Dravet Syndrome by Mutation Class<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.2 Incidence of Dravet Syndrome by Mutation Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.3 Seizure associated cases of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.4 Gender-specific Incidence of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.5 Age-specific Incidence of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\"><span>13 Spain<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1 Incident Population of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2 Mutations associated with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">13.2.1 Incidence of Dravet Syndrome by Mutation Class<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">13.2.2 Incidence of Dravet Syndrome by Mutation Type.<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3 Seizure associated cases of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.4 Gender-specific Incidence of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.5 Age-specific Incidence of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\"><span>14 United Kingdom<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.1 Incident Population of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.2 Mutations associated with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.1 Incidence of Dravet Syndrome by Mutation Class<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14.2.2 Incidence of Dravet Syndrome by Mutation Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.3 Seizure associated cases of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.4 Gender-specific Incidence of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14.5 Age-specific Incidence of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\"><span>15 Japan<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1 Assumptions and Rationale<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2 Incident Population of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3 Mutations associated with Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1 Incidence of Dravet Syndrome by Mutation Class<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2 Incidence of Dravet Syndrome by Mutation Type<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4 Seizure associated cases of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.5 Gender-specific Incidence of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.6 Age-specific Incidence of Dravet Syndrome<\/p>\n<p style=\"text-align: justify;\"><span>16 Treatment of Dravet Syndrome<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.1 Current Treatment Practices<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.1.1 First-Line Therapies: Valproic Acid and Clobazam<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.1.2 Second-Line Therapies<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.1.3 Third Line of Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">16.2 Treatment Algorithm<\/p>\n<p style=\"text-align: justify;\"><span>17 Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18 Organizations contributing toward Dravet Syndrome<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19 KOL&rsquo;s Views: Dravet Syndrome<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20 Case Studies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1 Anesthetic Management of Dravet Syndrome<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2 Dravet Syndrome and Parkinsonism<\/p>\n<p style=\"text-align: justify;\"><span>21 Marketed Drugs<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.1 Diacomit: Biocodex<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.1.1 Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.1.2 Mechanism of Action<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.1.3 Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.1.4 Advantages and Disadvantages<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.1.5 Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">21.2 Epidiolex: GW Pharmaceuticals<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.2.1 Drug Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.2.2 Mechanism of Action<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.2.3 Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.2.4 Advantages and Disadvantages<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.2.5 Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\"><span>22 Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.1 ZX-008: Zogenix<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.1 Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.2 Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.3 Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.4 Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.1 Soticlestat: Ovid Therapeutics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.1 Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.2 Other Development Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.3 Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.1.4 Safety and Efficacy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">22.2 Ataluren: PTC Therapeutics<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.2.1 Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22.2.2 Clinical Development<\/p>\n<p style=\"text-align: justify;\"><span>23 Dravet Syndrome: Seven Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">23.1 Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">23.2 Total Market Size of Dravet Syndrome in 7MM<\/p>\n<p style=\"text-align: justify;\"><span>24 Market Outlook by Country<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.1 The United States: Market Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.2 United States Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.2.1 Total Market Size of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.2.2 Dravet Syndrome Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.3 EU-5 Countries: Market Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.4 Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.4.1 Total Market Size of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.4.2 Dravet Syndrome Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.5 France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.5.1 Total Market Size of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.5.2 Dravet Syndrome Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.6 Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.6.1 Total Market Size of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.6.2 Dravet Syndrome Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.7 Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.7.1 Total Market Size of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.7.2 Dravet Syndrome Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.8 The United Kingdom Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.8.1 Total Market Size of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.8.2 Dravet Syndrome Market Size by Therapies<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.9 Japan: Market Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">24.10 Japan: Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.10.1 Total Market Size of Dravet Syndrome<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24.10.2 Dravet Syndrome Market Size by Therapies<\/p>\n<p style=\"text-align: justify;\"><span>25 Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>26 Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>27 Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>28 Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>28.1 Sources Used<\/span><\/p>\n<p style=\"text-align: justify;\"><span>29 DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>30 Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>31 About DelveInsight<\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dravet-syndrome-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dravet-syndrome-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Dravet Syndrome Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Dravet Syndrome (DS) in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dravet-syndrome-market-size-share-trends-epidemiology-forecast-till-2030_499491.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-499491","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=499491"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/499491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=499491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=499491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=499491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}